Senseonics Holdings, Inc. SENS

SENS Company Overview

Senseonics Holdings, Inc. is a U.S.-based medical technology company focused on the development and commercialization of long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company operates within the broader diabetes care, digital health, and medical device industries. Its core product platform is the Eversense CGM system, which combines a subcutaneous implantable glucose sensor, a removable smart transmitter, and a mobile application designed to provide real-time glucose readings and alerts over extended wear periods. The company primarily generates revenue through sales of CGM systems, sensors, related disposables, and commercialization partnerships.

Senseonics differentiates itself through its implantable sensor technology, which offers longer sensor life compared with many traditional transcutaneous CGM products. The company was founded in 1996 and evolved from a broader biosensor technology developer into a diabetes-focused CGM company. Over time, it secured regulatory approvals in the United States and Europe for multiple generations of the Eversense platform, including extended-duration sensors. Public filings and investor materials consistently identify long-duration implantable CGM technology as the company’s principal strategic positioning within the diabetes management market.